Skip to main content

Intellia Therapeutics

Intellia Therapeutics Inc is a clinical-stage biopharmaceutical enterprise headquartered in Cambridge, Massachusetts. The company specializes in developing curative therapies using CRISPR gene editing technology. Its research and clinical pipeline focuses on addressing the genetic basis of serious diseases by precisely editing target genes to restore biological function. Principal revenue is currently earned through research collaboration grants, development partnerships, and licensing agreements as its gene editing candidates advance through clinical trials. Intellia Therapeutics Inc is publicly listed on the Nasdaq Stock Market.

3 of the funds FundTelligence covers report a position in Intellia Therapeutics.

Legal name
Intellia Therapeutics Inc
Sector
Health Care
Country
United States
Funds holding it
3
Exposure themes
Gene Editing, Genetic Medicine, Precision Medicine & Genomics

Funds holding Intellia Therapeutics

Loading...